Genzyme Fights To Keep Anika's Monovisc Out Of US

Law360, New York (July 8, 2010, 2:09 PM EDT) -- Genzyme Corp. has launched an infringement suit against Anika Therapeutics Inc. in an effort to block a drug that allegedly infringes two patents covering osteoarthritis treatment technology.

Anika's injectable treatment Monovisc infringes claims of Genzyme's patents through its European and Canadian sales, and will do the same if approved for sale in the U.S., according to an 11-page complaint filed Wednesday in the U.S. District Court for the District of Massachusetts.

The three-count complaint asserts one claim of infringement of U.S. Patent Number 5,143,724 and two...
To view the full article, register now.